Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
Crossref DOI link: https://doi.org/10.1186/s12885-015-1751-6
Published Online: 2015-10-21
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Osumi, Hiroki
Shinozaki, Eiji
Suenaga, Mitsukuni
Kumekawa, Yosuke
Ogura, Mariko
Ozaka, Masato
Matsusaka, Satoshi
Chin, Keisho
Yamamoto, Noriko
Mizunuma, Nobuyuki
License valid from 2015-10-21